Fusion Pharmaceuticals has now raised $171m altogether to deliver cancer radiopharmaceuticals based on McMaster University research.
Fusion Pharmaceuticals, a Canada-based cancer radiopharmaceuticals developer spun out of McMaster University, attracted up to $20m yesterday from Canada Pension Plan Investment Board.
Fusion is working on cancer treatments that attach alpha radioactive particles to solid tumour cells to combat the disease without damaging healthy tissue.
The company’s lead candidate, FPI-1434, is soon to begin phase 1 clinical testing in an injected form for advanced, refractory solid tumours.
Fusion will put the fresh capital towards its growth…
